Inhalation and Nasal Spray Generic Drugs Market

Executive Summary

Inhalation and Nasal Spray Generic Drugs Market was valued at US $19.15 billion in 2021 and is projected to grow at 9.44% CAGR over the forecast period to reach US $32.91 billion by 2027. Inhalation and Nasal Spray Generic Drugs Market represented US $3.16 billion opportunity over 2019-2021 and estimated to create US $13.75 billion opportunity in 2027 over 2021.

Inhalation and Nasal Spray Generic Drugs from Consainsights analyses the Inhalation and Nasal Spray Generic Drugs Market in the Life Sciences industry over the forecast period to 2027.

Inhalation and Nasal Spray Generic Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Inhalation and Nasal Spray Generic Drugs segmentation includes Drug Class, Application and Geography.

Based on the Drug Class, the Inhalation and Nasal Spray Generic Drugs analysis covers Corticosteroids, Bronchodilators, Antihistamines, Decongestant Sprays, Other Drug Classes.

In Drug Class segment, Corticosteroids segment has highest cagr growth of 8.35%.

Based on the Application, the Inhalation and Nasal Spray Generic Drugs analysis covers Asthma, COPD, Allergic Rhinitis, Other Applications.

In Application segment, Asthma segment has highest cagr growth of 8.35%.

Based on the region, the Inhalation and Nasal Spray Generic Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Akorn Incorporated, Apotex, Beximco Pharma, Cipla Inc., Hikma (Roxane), Mylan N.V., Sandoz (Novartis AG), Sun Pharma (Ranbaxy), Teva Pharmaceuticals and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Drug Class

Introduction

In 2021, Corticosteroids segment has the highest revenue of US $7.85 billion and is expected to grow at CAGR of 8.35% by 2027 Corticosteroids segment has highest cagr growth of 8.35%.

Corticosteroids

Corticosteroids segment was valued at US $6.56 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $13.49 billion by 2027. Corticosteroids segment represented US $1.30 billion opportunity over 2019-2021 and estimated to create US $5.64 billion opportunity in 2027 over 2021.

Bronchodilators

Bronchodilators segment was valued at US $3.96 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $8.14 billion by 2027. Bronchodilators segment represented US $0.78 billion opportunity over 2019-2021 and estimated to create US $3.40 billion opportunity in 2027 over 2021.

Antihistamines

Antihistamines segment was valued at US $2.62 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $5.40 billion by 2027. Antihistamines segment represented US $0.52 billion opportunity over 2019-2021 and estimated to create US $2.26 billion opportunity in 2027 over 2021.

Decongestant Sprays

Decongestant Sprays segment was valued at US $1.86 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $3.83 billion by 2027. Decongestant Sprays segment represented US $0.37 billion opportunity over 2019-2021 and estimated to create US $1.60 billion opportunity in 2027 over 2021.

Other Drug Classes

Other Drug Classes segment was valued at US $1.00 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $2.05 billion by 2027. Other Drug Classes segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.86 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Asthma segment has the highest revenue of US $8.38 billion and is expected to grow at CAGR of 8.35% by 2027 Asthma segment has highest cagr growth of 8.35%.

Asthma

Asthma segment was valued at US $7.00 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $14.40 billion by 2027. Asthma segment represented US $1.38 billion opportunity over 2019-2021 and estimated to create US $6.02 billion opportunity in 2027 over 2021.

COPD

COPD segment was valued at US $4.86 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $10.00 billion by 2027. COPD segment represented US $0.96 billion opportunity over 2019-2021 and estimated to create US $4.18 billion opportunity in 2027 over 2021.

Allergic Rhinitis

Allergic Rhinitis segment was valued at US $2.58 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $5.31 billion by 2027. Allergic Rhinitis segment represented US $0.51 billion opportunity over 2019-2021 and estimated to create US $2.22 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $1.55 billion in 2019 and is projected to grow at 8.35% CAGR over the forecast period to reach US $3.19 billion by 2027. Other Applications segment represented US $0.31 billion opportunity over 2019-2021 and estimated to create US $1.34 billion opportunity in 2027 over 2021.